A prediction model for 5-year cardiac mortality in patients with chronic heart failure using 123I-metaiodobenzylguanidine imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 9, 2014, Pages 1673-1682

  Nakajima, Kenichi ^a   Nakata, Tomoaki ^b,j   Yamada, Takahisa ^c   Yamashina, Shohei ^d   Momose, Mitsuru ^e   Kasama, Shu ^f   Matsui, Toshiki ^g   Matsuo, Shinro ^a   Travin, Mark I ^h   Jacobson, Arnold F ⁱ  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Osaka Prefectural General Medical Center   (Japan)

^d TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f Cardiovascular Hospital of Central Japan   (Japan)

^g Shiga General Hospital   (Japan)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ GE HEALTHCARE   (United States)

^j HAKODATE GORYOUKAKU HOSPITAL   (Japan)

more..

Author keywords

Cardiac mortality; Chronic heart failure; Prediction model; Risk stratification

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; JAPAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; NOMOGRAM; OUTCOME ASSESSMENT; PARAMETERS; SUDDEN CARDIAC DEATH; SYMPATHETIC INNERVATION; ANALYSIS OF VARIANCE; CHRONIC DISEASE; DEATH; DIAGNOSTIC USE; RISK; SCINTISCANNING; STATISTICAL MODEL;

3-IODOBENZYLGUANIDINE; ANALYSIS OF VARIANCE; CHRONIC DISEASE; DEATH; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RISK;

EID: 84906055396     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2759-x     Document Type: Article

References (28)

1. Kalogeropoulos AP, Georgiopoulou VV, Butler J. Clinical adoption of prognostic biomarkers: the case for heart failure. Prog Cardiovasc Dis. 2012;55:3-13.
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;62:e147-239. doi:10.1161/CIR. 0b013e31829e8776.
3. Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, et al. The normal and abnormal distribution of the adrenomedullary imaging agentm-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med. 1983;24:672-82. (Pubitemid 13016087)
4. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-7.
5. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579-90. (Pubitemid 29015414)
6. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426-35.
7. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212-21.
8. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147-59. (Pubitemid 351844881)
9. Kuwabara Y, Tamaki N, Nakata T, Yamashina S, Yamazaki J. Determination of the survival rate in patients with congestive heart failure stratified by 123I-MIBG imaging: a meta-analysis from the studies performed in Japan. Ann Nucl Med. 2011;25:101-7.
10. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-33. (Pubitemid 43739439)
11. Kuramoto Y, Yamada T, Tamaki S, Okuyama Y, Morita T, Furukawa Y, et al. Usefulness of cardiac iodine-123 meta-iodobenzylguanidine imaging to improve prognostic power of Seattle heart failure model in patients with chronic heart failure. Am J Cardiol. 2011;107:1185-90.
12. Ketchum ES, Jacobson AF, Caldwell JH, Senior R, Cerqueira MD, Thomas GS, et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012;19:1007-16.
13. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of 123I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6:772-84.
14. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001;42:1757-67. (Pubitemid 34016342)
15. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231-8. (Pubitemid 36092191)
16. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy - Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J. 2001;141:645-52. (Pubitemid 32260734)
17. Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun. 1999;20:529-35. (Pubitemid 29509990)
18. Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments - comparison with neurohumoral factors. Circ J. 2002;66:537-43. (Pubitemid 34733491)
19. Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med. 2008;49:907-14. (Pubitemid 351793431)
20. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116:392-8. (Pubitemid 47196544)
21. Doi T, Nakata T, Hashimoto A, Yuda S, Wakabayashi T, Kouzu H, et al. Synergistic prognostic values of cardiac sympathetic innervation with left ventricular hypertrophy and left atrial size in heart failure patients without reduced left ventricular ejection fraction: a cohort study. BMJ Open. 2012;2:e001015.
22. Shaw LJ, Min JK, Hachamovitch R, Hendel RC, Borges-Neto S, Berman DS. Nomograms for estimating coronary artery disease prognosis with gated stress myocardial perfusion SPECT. J Nucl Cardiol. 2012;19:43-52.
23. Nakajima K, Matsuo S, Okuyama C, Hatta T, Tsukamoto K, Nishimura S, et al. Cardiac event risk in Japanese subjects estimated using gated myocardial perfusion imaging, in conjunction with diabetes mellitus and chronic kidney disease. Circ J. 2012;76:168-75.
24. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40. (Pubitemid 26428217)
25. Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225-33. (Pubitemid 351225660)
26. Nishisato K, Hashimoto A, Nakata T, Doi T, Yamamoto H, Nagahara D, et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDs. J Nucl Med. 2010;51:1241-9.
27. Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2012;39:113-9.
28. Kelesidis I, Travin MI. Use of cardiac radionuclide imaging to identify patients at risk for arrhythmic sudden cardiac death. J Nucl Cardiol. 2012;19:142-52. quiz 153-7.